Recent Quotes (30 days)

You have no recent quotes
chg | %

Critical Outcome Technologies Inc.  

(Public, CVE:COT)   Watch this stock  
Find more results for COT
-0.06 (-4.80%)
Nov 21 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.19 - 1.23
52 week 1.00 - 6.40
Open 1.23
Vol / Avg. 13,550.00/12,266.00
Mkt cap 17.75M
P/E     -
Div/yield     -
EPS -0.28
Shares 14.92M
Beta -0.12
Inst. own     -
Dec 18, 2017
Q2 2018 Critical Outcome Technologies Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Sep 29, 2017
Q1 2018 Critical Outcome Technologies Inc Earnings Release
Sep 12, 2017
Critical Outcome Technologies Inc at Rodman & Renshaw Global Investment Conference
Aug 28, 2017
Q4 2017 Critical Outcome Technologies Inc Earnings Release

Key stats and ratios

Q3 (Jul '17) 2017
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -29.40% -114.03%
Return on average equity -165.38% -275.56%
Employees 10 -
CDP Score - -


700 Collip Cir Suite 213
+1-519-8585157 (Phone)
+1-519-8585179 (Fax)

Website links


Critical Outcome Technologies Inc. (COTI) is a clinical-stage biopharmaceutical company. The Company is engaged in drug discovery and development. The Company uses machine learning to develop targeted therapies thereby managing the timeline and cost of getting new drug therapies to market. The Company's artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds with a high probability of being developed from disease specific drug discovery through chemical optimization and preclinical testing. The CHEMSAS platform technology is designed for small molecules, and as a drug candidate discovery engine can be applied to any disease target with information for the target of interest. The Company's initial focus is in advancing the treatment of cancer with the Company's lead compound, COTI-2, having a p53-dependent mechanism of action demonstrating selective and potent anti- cancer activity.

Officers and directors

John C. Drake Independent Chairman of the Board
Alison Silva President, Chief Executive Officer, Director
Gene Kelly Chief Financial Officer
Richard T. Ho M.D., Ph.D. Chief Scientific Officer
Age: 52
Bharatt M. Chowrira Ph.D., J.D. Director
Age: 52
Douglas S. Alexander Independent Director
Bruno C. Maruzzo Independent Director
Age: 61
Dave Sanderson Independent Director